No significant associations for PFS could be seen in whether previously treated with bevacizumab (P = 0.874), K-RAS status (P = 0.150), tumor sites (P = 0.321), and any kind of PD-1 inhibitors (P = 0.477). This evidence concerns the gene KRAS and neoplasm.